Amarin (AMRN) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Shattuck Labs (STTK) has outperformed Amarin (AMRN) over the past year, gaining 119.7% versus a loss of 35.5%. Over five years, STTK leads with a -52.0% price change compared with -85.5% for AMRN. Shattuck Labs is the larger company by market cap ($454.2 million vs $444.4 million), about 1.0 times the size, while Amarin is growing revenue faster (-6.5% vs -82.5%).
Amarin converts more of its revenue into profit, with a net margin of -18.2% versus -4880.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | STTK |
|---|---|---|
| Share price | $10.57 | $4.46 |
| Market cap | $444.39M | $454.22M |
| 1-day change | -6.13% | -1.98% |
| YTD return | -24.28% | +22.19% |
| 1-year return | -35.47% | +119.70% |
| 5-year return | -85.48% | -51.99% |
| Forward P/E | 10.79 | — |
| EPS (TTM) | $-0.80 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $213.65M | $1.00M |
| Revenue growth (YoY) | -6.55% | -82.52% |
| Net income (latest FY) | $-38.80M | $-48.81M |
| Gross margin | 56.57% | — |
| Operating margin | -23.48% | -5150.80% |
| Net margin | -18.16% | -4880.90% |
| 52-week high | $17.31 | $8.33 |
| 52-week low | $10.56 | $1.93 |
| Distance from 52-week high | -38.94% | -46.46% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +22.99% | +245.29% |
| Average volume | 79.50K | 1.20M |
| Shares outstanding | 42.04M | 101.84M |
| Employees | 80 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed AMRN by 155.2 percentage points over the past year.
- Amarin is more profitable, keeping -18.2 cents of every revenue dollar as net income versus -4880.9 cents for Shattuck Labs.
- Amarin grew revenue faster in its latest fiscal year (-6.55% vs -82.52%).
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
AMRN vs STTK FAQ
Which is bigger, Amarin or Shattuck Labs?
Shattuck Labs (STTK) is larger, with a market capitalization of $454.22M compared with $444.39M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or STTK?
STTK returned +119.70% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.